Study for Adolescents and Adults With Ornithine Transcarbamylase Deficiency to Evaluate Safety and Tolerability of ARCT-810
Study sponsor: Arcturus Therapeutics, Inc.
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2024-10-31Actual
Enrollment · participants8Actual
Source updated2025-09-26Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.